Tempest Therapeutics (TPST) Proxy filing summary

Executive summary

• A special meeting of stockholders was reconvened to vote on amending the Restated Certificate of Incorporation, specifically to replace supermajority voting requirements and permit stockholder action by written consent.

• The meeting was adjourned due to insufficient votes and will reconvene on September 15, 2026, to allow more time for shareholder participation.

• 71.6% of outstanding shares were represented at the meeting, constituting a quorum.

Voting matters and shareholder proposals

• The main proposal seeks to amend the certificate to eliminate certain supermajority voting requirements and allow action by written consent.

• Approval requires at least 75% affirmative votes of all shares entitled to vote.

• No changes have been made to the proposal since the initial distribution.

• Proxies already submitted remain valid unless revoked.

Board of directors and corporate governance

• Directors and executive officers are participating in the proxy solicitation process.

• Information about directors and executive officers is available in recent SEC filings.